Introduction
Multiple myeloma (MM) is a plasma cell malignancy that remains incurable despite use of conventional treatment with alkylating agents, anthracyclines, and corticosteroids (Gregory et al., 1992; Group, 1998) , as well as high dose therapy and stem cell transplantation (Fermand et al., 1998; Lenhoff et al., 2000; Attal and Harousseau, 2001) . To overcome resistance to conventional therapeutics, novel agents have recently been developed. These novel agents target not only MM cells but also the bone marrow (BM) microenvironment, and thereby can overcome cell adhesion-mediated-drug resistance (CAM-DR) associated with growth arrest (Damiano et al., 1999; Hazlehurst et al., 2000) , NF-kB activation (Landowski et al., 2003) , and cytokine (i.e., IL-6, IGF-1, VEGF) secretion in the BM milieu. Among these novel agents, Velcadet) has demonstrated significant antitumor activity against drug-resistant MM cells both in vitro (Hideshima et al., 2001a (Hideshima et al., , b, 2003c Mitsiades et al., 2002a) , in vivo using preclinical models (LeBlanc et al., 2002) , and in clinical studies (Orlowski et al., 2002; Richardson et al., 2003) .
PS-341 directly inhibits proliferation, as well as induces caspase activation and apoptosis (Hideshima et al., 2001b (Hideshima et al., , 2003c Mitsiades et al., 2002a) , in human MM cell lines and freshly isolated patient MM cells, despite the induction of CDK inhibitors p21
Cip1 and p27
Kip1 (Hideshima et al., 2001b) . Importantly, PS-341 also adds to the anti-MM activity of dexamethasone (Dex) (Hideshima et al., 2001b) and CC-5013 (Revlimidt) (Mitsiades et al., 2002b) , and inhibits MM cell adherence to bone marrow stromal cells (BMSCs) by downregulating adhesion molecules (ICAM-1 and VCAM-1) (Hideshima et al., 2001a) even in drugresistant MM cells. IL-6 in the BM milieu does not protect against PS-341-induced apoptosis. PS-341 triggers upregulation of heat-shock proteins (Hsps) and activation of c-Jun NH 2 -terminal kinase (JNK) (also known as stress-activated protein kinase (SAPK) (Hideshima et al., 2003c) . Furthermore, PS-341 induces cleavage of DNA-protein kinase catalytic subunit (PKcs) and ataxia telangiectasia mutated (ATM), suggesting that PS-341 also inhibits DNA repair (Hideshima et al., 2003c) . These data further support our observation that PS-341 enhances sensitivity of MM cells to conventional chemotherapeutic agents, especially to DNA-damaging agents (i.e., doxorubicin (Dox), melphalan) (Mitsiades et al., 2003) . Our recent study also demonstrated that PS-341 downregulates the cytoplasmic domain gp130 on the cell surface of MM cell lines in a caspase-dependent mechanism, thereby inhibiting IL-6 signaling cascades (Hideshima et al., 2003a) .
A phase II trial of PS-341 treatment in 202 patients with refractory relapsed MM demonstrated 35% responses, including 10% complete and near complete responses ; however, 65% of patients did not respond to PS-341. Based upon our preclinical studies (Hideshima et al., 2001b (Hideshima et al., , 2003c Mitsiades et al., 2002a Mitsiades et al., , 2003 , two ongoing clinical trials using PS-341 plus pegylated liposomal Dox and melphalan (Yang et al., 2003) show great promise that combination therapy can overcome resistance to DNA-damaging agents. Whether novel agents can be used to similarly overcome PS-341 resistance is unknown. Specifically, lysophosphatidic acid (LPA) is a serum phospholipid that acts via specific G-protein-coupled receptors for multiple signaling pathways, including cascades initiated by small GTPases RAS, to mediate tumor cell migration and invasion (Mills and Moolenaar, 2003) . Recent studies have shown that inhibition of LPA acyltransferase (LPAAT)-b inhibits both the Ras/Raf/Erk and PI3K/ Akt signaling cascades . Importantly, we have recently reported that LPAAT-b inhibitors block growth of even drug-resistant MM cells (Hideshima et al., 2003b) . Whether LPAAT-b inhibitors can similarly overcome PS-341 resistance remains unknown.
In this study, we examined the biologic effect of LPAAT-b inhibition in PS-341-resistant tumor cells. Specifically, we characterized apoptotic signaling triggered by LPAAT-b inhibitor CT-32615 in both PS-341-sensitive and-resistant cells, and demonstrated significant growth inhibition induced by CT-32615 even in PS-341-resistant cells. Our data therefore demonstrate that LPAAT-b inhibitor induce growth inhibition in PS-341-resistant cells, providing the framework for its evaluation to overcome clinical resistance to proteasome inhibitors and improve patient outcome in MM.
Results

DHL-4 cell line is resistant to PS-341 treatment
We first examined the effect of PS-341 on growth of both MM. 1S and DHL-4 cell lines. MM.1S and DHL-4 cells were cultured with increasing concentrations (1.25-80 nM) of PS-341 for 24 h ( Figure 1a ) and 48 h (Figure 1b) . IC 50 of PS-341 treatment in MM.1S cells at 24 and 48 h treatment was 5 and 3 nM, respectively, as assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyl tetrazolium bromide; PI, propidium iodine) assay; in contrast, PS-341 did not achieve IC 50 in DHL-4 cells even at 80 nM concentration. This result is consistent with our previous report showing that DHL-4 cells are resistant to PS-341 treatment .
DHL-4 cells express low levels of caspase-8 and -3
We next examined the molecular mechanisms of resistance to PS-341 treatment in DHL-4 cells. DHL-4 cells were treated with PS-341 (40 nM) for 6 and 8 h. As in our previous studies (Mitsiades et al., 2002a; Hideshima et al., 2003c) , PS-341 induced cleavage of caspase-3, caspase-9, caspase-3, and poly (ADP)-ribose polymerase (PARP) in MM.1S cells, in a time-dependent fashion. In contrast, the expression of caspase-8 and -3 in DHL-4 cells was very low, and no cleavage was recognized in caspase-8, caspase-9, caspase-3, or PARP after PS-341 treatment (Figure 2a ). These results suggest that low expression of caspase-8 and -3 is associated with PS-341 resistance in DHL-4 cells. . No constitutive expression of Hsp27 was observed in MM.1S cells; however, PS-341 markedly induced its expression in a timedependent fashion. On the other hand, DHL-4 cells constitutively highly express Hsp27, which is not altered by PS-341 treatment. Interestingly, Hsp70 expression was also upregulated in MM.1S, but not in DHL-4, cells by PS-341 treatment (Figure 2c ). These results suggest that a stress response, which causes downstream caspase activation, is triggered in PS-341-sensitive MM.1S, but not in PS-341-resistant DHL-4 cells.
PS-341 does not trigger JNK/SAPK activation in DHL-4 cells
DHL-4 cells are resistant to anti-MM agents
Since DHL-4 cells express low levels of caspase-3 and -8, we next examined whether DHL-4 cells are also resistant to other conventional (Dex, Dox, As 2 O 3 ), and novel (Revlimid, and CT-32615) 
CT-32615 does not induce caspase/PARP cleavage and apoptosis
We next examined whether CT-32615 could cleave caspase/PARP in DHL-4 cells by Western blotting with anti-caspase-7, caspase-3, PARP, and DFF Abs. As in our previous studies (Hideshima et al., 2003b) , CT-32615 induced sequential cleavage of caspase-7, caspase-3, and PARP in MM.1S cells in a dose-dependent fashion. In contrast, none of these proteins was cleaved after CT-32615 treatment of DHL-4 cells (Figure 4c ). Moreover, DFF45 expression in MM.1S cells was markedly downregulated by CT-32615 treatment in MM.1S cells, but was not altered in DHL-4 cells. These results suggest that growth inhibition triggered by CT-32615 is not mediated via caspase-dependent mechanisms.
To further confirm these data, we examined morphological changes in DHL-4 cells induced by PS-341 treatment. Although PS-341-treated MM.1S cells demonstrated cell shrinkage and condensation of chromatin in the nucleus associated with apoptosis, these morphological changes were not observed in CT-32615-treated DHL-4 cells. Importantly, cell swelling and lysis were recognized in DHL-4 cells (Figure 5a ). To further assess for apoptosis triggered by CT-32615, we performed flow cytometric analyses of Apo2.7 and TUNEL staining. Although CT-32615-treated MM.1S cells showed 78 and 68% positive staining for Apo2.7 and TUNEL, respectively, CT-32615-treated DHL-4 cells were neither Apo2.7 nor TUNEL positive (Figure 5b ), consistent with both Western blotting and morphological assessments.
To confirm the role of caspases in CT-32615-induced cytotoxicity, DHL-4 cells were cultured with CT-32615, either in the absence or presence of pan-caspase inhibitor Z-VAD-FMK. As expected, cytotoxicity triggered by CT-32615 in MM.1S cells, but not in DHL-4 cells, was abrogated by Z-VAD-FMK (Figure 5c ). Taken together, these results strongly suggest that CT-32615-induced cytotoxicity in DHL-4 cells is mediated via necrosis. We next further delineated molecular mechanisms whereby CT-32615 induces necrosis in DHL-4 cells. Since ATP is required and consumed during apoptosis (Kim et al., 2003) , we first measured intracellular ATP levels before and after treatment with CT-32615 in MM.1S cells and DHL-4 cells. As expected, ATP level was markedly decreased after CT-32615 treatment in MM.1S cells, associated with about 60% apoptotic cell death (Figure 6a ). In contrast, ATP level was 1.9-fold increased after CT-32615 treatment in DHL-4 cells, even though 70% growth inhibition was observed (Figure 6b) . Similar results were recognized at as early as 6 h treatment with CT-32615 in DHL-4 cells (data not shown). These results strongly suggest that CT-32615 triggers accumulation of ATP by inhibiting ATP consumption, resulting in ATPstarved conditions in the cells. We and others have previously shown that CT-32615 induces a transient increase in G2/M phase in tumor cells Hideshima et al., 2003b) , and we therefore next similarly examined the cell cycle profile of DHL-4 cells after CT-32615 treatment. Consistent with our previous studies, CT-32615 induced an increase (19-42%) in G2/M phase MM.1S cells (Figure 7a ), associated with time-dependent upregulation of p21 Cip1 (Figure 7b ). Importantly, CT-32615 also induced G2/M arrest (increase from 23 to 65%) in DHL-4 cells (Figure 7c ), without alteration of p21 Cip1 expression (Figure 7d ). Since cdc25c and cdc2 regulate G2/M transition, we next further examined phosphorylation and expression of these proteins in DHL-4 cells after CT-32615 treatment. Post treatment of DHL-4 cells with 200 nM CT-32615 for 12, 24, 36, and 48 h, both phosphorylation and expression of cdc25c and cdc2 were downregulated. These results suggest that there are at least two distinct mechanisms whereby CT-32615 can induce G2/M arrest. Ongoing studies are delineating the molecular mechanisms whereby CT-32615 downregulates cdc25c and cdc2 in DHL-4 cells.
CT-32615 overcomes PS-341 resistace in patient tumor cells
We have reported anti-MM activity of PS-341 in a phase II clinical trial treating patients with relapsed 
Discussion
Despite use of conventional therapies with alkylating agents, anthracyclines, and corticosteroids (Gregory et al., 1992; Group, 1998) , as well as high dose therapy and stem cell transplantation (Lenhoff et al., 2000; Attal and Harousseau, 2001) , MM remains incurable. Recently, novel agents targeting not only MM cells but also their BM microenvironment have been shown to overcome resistance to conventional chemotherapeutic agents Hideshima et al., 2003d) . Among these novel agents, PS-341 (bortezomib, Velcadet) demonstrates potent activity against drug-resistant MM cells in vitro (Hideshima et al., 2001b (Hideshima et al., , 2003a Mitsiades et al., 2002a) , in vivo in preclinical models (LeBlanc et al., 2002) , and in clinical trials . PS-341 directly induces JNK/caspase/PARP apoptotic signaling in human MM cell lines and patient MM cells (Hideshima et al., 2001b (Hideshima et al., , 2003c Mitsiades et al., 2002a) , as well as overcomes paracrine MM cell growth and survival in the BM milieu (Hideshima et al., 2001a, b; LeBlanc et al., 2002) . Our recent study also demonstrated that PS-341 induces caspase-dependent downregulation of gp130 on MM cells, thereby inhibiting IL-6-triggered signaling in tumor cells within the BM microenvironment (Hideshima et al., 2003a). Most importantly, we have reported that PS-341 achieved 35% responses, including complete responses, prolonged survival; and achieved clinical benefit in patients with relapsed and refractory MM . However, 65% of patients were nonresponders, and some patients developed PS-341 resistance. To overcome resistance, several therapeutic strategies have already been employed. First, we have shown that PS-341 induces DNA-dependent protein kinase catalytic subunit cleavage (Hideshima et al., 2003c) , thereby inhibiting DNA repair and significantly enhancing sensitivity to DNA-damaging agents (i.e., Dox and melphalan) (Mitsiades et al., 2003) and histone deacetylase inhibitors . Based upon these preclinical results, clinical trials using the combination of PS-341 with DNA-damaging agents Doxil and melphalan have already shown great promise in overcoming conventional drug resistance Yang et al., 2003) .
We have recently shown that LPAAT-b inhibitors induce significant growth inhibition in MM cell lines, as well as in patient MM cells, via caspase/PARPdependent apoptosis. Importantly, neither IL-6 nor insulin-like growth factor (IGF)-1 protects against CT-32615-triggered apoptosis. Moreover, although binding of MM cells to BMSCs both augments MM cell growth and protects against Dex-induced apoptosis, CT-32615 induces apoptosis even of adherent MM cells (Hideshima et al., 2003b) . Since CT-32615 is effective against MM cells resistant to conventional therapies, we here tested whether CT-32615 could induce cytotoxicity even in PS-341-resistant DHL-4 cells .
We first characterized the molecular mechanisms mediating PS-341 resistance in DHL-4 cells. Consistent with our previous studies, IC 50 after treatment with 80 nM PS-341 for 48 h is 3 nM in MM.1S cells, but not achieved in DHL-4 cells. Since we have shown that PS-341-induced cytotoxicity is mediated via JNK/ caspase/PARP apoptotic signaling (Hideshima et al., 2001b (Hideshima et al., , 2003c Mitsiades et al., 2002a) , we next similarly examined whether PS-341 induced these changes in DHL-4 cells. Surprisingly, the baseline expression of caspase-8 and -3 is markedly lower in DHL-4 cells than in MM.1S cells; and caspase-8, -9, -3 or PARP cleavage is not triggered in DHL-4 cells by PS-341. Furthermore, JNK activation is also not induced in DHL-4 cells by PS-341. Since JNK activation and caspase/PARP cleavage is a hallmark of PS-341-induced apoptosis, these data suggest that PS-341 resistance in DHL-4 cells is mediated, at least in part, by inhibition of stress response as well as low caspase-8 and caspase-3 expression. Indeed DHL-4 cells are resistant not only to PS-341 but also to Dex, Dox, Mel, Revlimid (CC-5013), and As 2 O 3 , suggesting that they are multidrug resistant. In contrast to these agents and of great potential clinical importance, LPAAT-b inhibitor CT-32615 demonstrates potent cytotoxicity in DHL-4 cells, with IC 50 of 70 nM at 72 h culture.
We have previously shown that LPAAT-b inhibitor CT-32615 has significant cytotoxicity against MM cell lines resistant to conventional (Dex, Dox, and Mel) therapeutic agents. It induces transient G2/M cell cycle arrest, associated with upregulation of p21
Cip1
; triggers JNK activation; induces sequential cleavage of caspase-7, -3, and PARP; followed by apoptosis (Hideshima et al., 2003b) . Here, we demonstrate that CT-32615 also induces transient G2/M arrest in PS-341-resistant DHL-4 cells. Although we have previously shown that CT-32615-induced G2/M arrest is mediated via upregulation of p21
, but not p27 Kip1 , in MM.1S cells, neither p21
Cip1 nor p27 Kip1 were induced in CT-32615-treated, G2/M arrested, DHL-4 cells. Importantly, CT-32615 downregulates cdc25c and cdc2, known to regulate G2/ M transition, in DHL-4 cells. Ongoing studies will delineate the molecular mechanisms whereby CT-32615 induces downregulation of those cell cycle-regulating proteins.
We demonstrate that caspase-7, -3 or PARP are not cleaved after CT-32615 treatment in DHL-4 cells. DFF45 (Inohara et al., 1998; Liu et al., 1998) , which plays a crucial role in CT-32615-induced apoptosis in MM.1S cells, also was not cleaved in CT-32615-treated DHL-4 cells. Based upon these results, we hypothesized that CT-32615-induced cytotoxicity is not mediated via apoptosis. Indeed, morphological changes assessed by microscopy and TUNEL staining further confirm that CT-32615-induced cytotoxicity in DHL-4 cells is not apoptosis, but rather necrosis. We next therefore measured ATP levels in both DHL-4 and MM.1S cells before and after CT-32615 treatment, since ATP has been shown to play a crucial role in both necrosis and apoptosis (Kim et al., 2003) . In contrast to apoptotic cell death, which requires and consumes ATP, necrosis is a consequence of ATP depletion. As expected, ATP was significantly decreased by CT-32615 treatment, which triggered caspase-dependent apoptosis in MM.1S cells. In contrast, ATP level was increased after CT-32615 treatment in DHL-4 cells, even though 80% cell growth inhibition was observed. These results strongly suggest that CT-32615 does not trigger consumption, but rather blocks usage of ATP, thereby resulting in ATP-depleted conditions in DHL-4 cells.
Our results therefore indicate that LPAAT-b inhibitor CT-32615 mediates apoptosis versus necrosis in PS-341-sensitive and -resistant cells, respectively. Our observation that LPAAT-b inhibitors abrogate growth of tumor cells from patients who do not respond to PS-341 provides the preclinical framework for its evaluation to overcome clinical resistance to proteasome inhibitors and thereby improve patient outcome in MM.
Materials and methods
Cell lines and patients BM plasma cells
Dex-sensitive (MM. 1S) human MM cell line was kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). PS-341-resistant DHL-4 was kindly provided by Dr Margaret Shipp (Dana-Farber Cancer Institute, Boston). Both cell lines were cultured in RPMI-1640 containing 10% fetal bovine serum (FBS, Sigma Chemical Co., St Louis, MO, USA), 2 mM L-glutamine, lysophosphatidic acid acyltransferase-b inhibitor overcomes PS-341 resistance T Hideshima et al 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA). Patient plasma cells were purified from patient bone marrow BM aspirates as described previously (Hideshima et al., 2003c .
Reagents and antibodies
PS-341 is provided from Millennium Pharmaceuticals (Cambridge, MA, USA). The LPAAT-b inhibitor used was CT-32615, which is an analog of CT-32228 (N-(4-bromo-phenyl)-6-(5-chloro-2-methyl-phenyl)- [, 1998 , 5]triazine-2,4-diamine) (Cell Therapeutics Inc., Seattle, WA, USA) as described previously Hideshima et al., 2003b) . As 2 O 3 was provided by Cell Therapeutics Inc. Dex, Dox, and melphalan (Mel) are from Sigma (St Louis, MO, USA). Revlimid (CC-5013) is from Celgene Corporation (Warren, NJ, USA).
The Abs used in Western blotting are anti-caspase-3 (BD Pharmingen, San Diego, CA, USA); anti-caspase-7, caspase-9, PARP, phospho-SEK1, phospho-SAPK, phospho-c-Jun, Hsp27, DFF 45/35, phospho-cdc25c (Ser216), phospho-cdc2 (Thr161), phospho-cdc2 (Tyr15), and cdc2 (Cell Signaling, Beverly, MA, USA); anti-JNK-1, Hsp70, p21 Cip1 , p27 Cip1 , cdc25c, and a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Pan-caspase inhibitor Z-VAD-FMK was purchased from Calbiochem (San Diego, CA, USA).
Growth inhibition assay
The inhibitory effect of PS-341 and CT-32615 on cell growth was assessed by measuring MTT dye absorbance of the cells, as described previously (Hideshima et al., 2003b) . Cells from 48 and 72 h cultures were pulsed with 10 ml of 5 mg/ml MTT to each well for the last 4 h of 48 and 72 h cultures, followed by 100 ml isopropanol containing 0.04 N HCl. Absorbance was measured at 570 nm using a spectrophotometer (Molecular Devices Corp., Sunnyvale CA, USA). All experiments were performed in quadruplicate. Morphological examination of DHL-4 cells treated with CT-32615 was assessed using an inverted microscope (Olympus, Tokyo, Japan).
Immunoblotting
Cells cultured with PS-341 or CT-32615 were harvested, washed, and lysed using lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 5 mg/ml leupeptine, and 5 mg/ml aprotinin. Whole-cell lysates were subjected to SDSNPAGE, transferred to nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA), and immunoblotted with specific Abs, as described previously .
Flow cytometric analysis
For cell cycle analysis, MM.1S. and DHL-4 cells cultured for 48 h in CT-32615 (25-200 nM) or control media were harvested, washed with phosphate-buffered saline (PBS), fixed with 70% ethanol, and treated with 10 mg/ml of RNase (Roche Diagnostics Corp., Indianapolis, IN, USA). Cells were then stained with propidium iodine (PI, Sigma) (5 mg/ml).
For detection of apoptosis, DHL-4 cells treated with CT-32615 were harvested and stained with APO2.7 Ab (Immunotech, Marseille, France) (Koester et al., 1997) according to manufacturer's instruction. Apoptosis was also assessed by using METASTAIN Apoptosis Kit Directt (MBL Medical & Biological Laboratory Co., LTD., Nagoya, Japan), according to manufacturer's instructions.
ATP bioluminescence assay
Intracellular ATP level in MM.1S. and DHL-4 cells treated with CT-32615 for 48 h was assessed using the ATP Bioluminescence Assay Kitt (Roche Diagnostics, Penzberg, Germany) according to the manufacturer's protocol; luminescence was measured by luminometer (Model LB0507, EG & G Wallac, Gaithersburg, MD, USA). Cell viability of the same samples was assessed by trypan blue exclusion.
Statistical analysis
Statistical significance of differences observed in drug-treated vs control cultures was determined using the Student's t-test. The minimal level of significance was Po0.05.
Abbreviations MM, multiple myeloma; LPA, lysophosphatidic acid; LPAAT, LPA acyltransferase; PARP, poly (ADP)-ribose polymerase; Dex, dexamethasone; Dox, doxorubicin; BM, bone marrow; BMSC, BM stromal cell; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyl tetrazolium bromide; PI, propidium iodine; Hsp, heat-shock protein; JNK, c-Jun NH 2 -terminal kinase; DFF, DNA fragmentation factor.
